DIM
ALLO icon

DLK Investment Management’s Allogene Therapeutics ALLO Stock Holding History

DLK Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$12.4K – 90
2025
Q3 		$12.4K Buy
+10,000
New +$11.9K ﹤0.01% 90

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

DLK Investment Management's ALLO Position: Q4 2025 in Review

DLK Investment Management sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 10,000 shares — an estimated $12.4K sold.

DLK Investment Management first reported a position in ALLO in Q3 2025 and held it in 1 quarter. The position peaked at $12.4K in Q3 2025. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • DLK Investment Management reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • DLK Investment Management sold 10,000 Allogene Therapeutics shares in Q4 2025, an estimated $12.4K.
  • DLK Investment Management first reported a position in Allogene Therapeutics in Q3 2025 and held it in 1 quarter.
  • DLK Investment Management's Allogene Therapeutics position peaked at $12.4K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on DLK Investment Management's 13F filing for Q4 2025, filed 14 Jan 2026.